Alphatec (NASDAQ:ATEC) EVP Sells $833,260.75 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 60,425 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $13.79, for a total transaction of $833,260.75. Following the completion of the sale, the executive vice president owned 349,500 shares in the company, valued at $4,819,605. The trade was a 14.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

David Sponsel also recently made the following trade(s):

• On Wednesday, December 10th, David Sponsel sold 21,106 shares of Alphatec stock. The shares were sold at an average price of $20.79, for a total value of $438,793.74.
• On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The shares were sold at an average price of $21.45, for a total value of $21,192.60.

Alphatec Stock Up 2.4%

Shares of NASDAQ:ATEC traded up $0.32 on Friday, hitting $13.82. 2,253,779 shares of the company’s stock were exchanged, compared to its average volume of 3,827,759. Alphatec Holdings, Inc. has a 1-year low of $8.81 and a 1-year high of $23.29. The company has a market capitalization of $2.05 billion, a PE ratio of -13.29 and a beta of 1.01. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The firm’s 50-day moving average is $19.03 and its 200 day moving average is $16.98.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Alphatec by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after buying an additional 3,196 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Alphatec during the 1st quarter worth approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Alphatec by 18.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock worth $2,696,000 after acquiring an additional 41,264 shares during the period. Truist Financial Corp purchased a new position in shares of Alphatec in the 2nd quarter valued at approximately $216,000. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Alphatec by 25.9% in the second quarter. KLP Kapitalforvaltning AS now owns 23,800 shares of the medical technology company’s stock valued at $264,000 after purchasing an additional 4,900 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on ATEC shares. Lake Street Capital set a $25.00 price objective on shares of Alphatec and gave the stock a “buy” rating in a report on Friday, October 31st. JPMorgan Chase & Co. initiated coverage on shares of Alphatec in a research report on Friday, October 24th. They issued an “overweight” rating and a $19.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alphatec in a research report on Monday, December 29th. Loop Capital set a $25.00 price objective on Alphatec in a report on Wednesday, December 10th. Finally, Stifel Nicolaus initiated coverage on Alphatec in a research report on Tuesday, October 28th. They set a “buy” rating and a $20.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $22.82.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.